Tomahawk, WI 06/16/2014 (Basicsmedia) – Multiple myeloma remains a tough challenge for oncologists in particular and medical science in general. Hence, in what might be good news for multiple myeloma sufferers, Karyopharm Therapeutics Inc (NASDAQ:KPTI) has reported some spectacularly positive results from its ongoing Phase I trials of its novel therapeutic agent Selinexor.

Spectacular Results

Selinexor combined with low-dose dexamethasone has shown quite promising results in a small study group of eight patients. The reported clinical benefit response rate of 75% and overall response rate of 50% led to the stock rising by a whopping 93.51% on Friday, June 13 to end the day at $47.12.

The patients who underwent the trial had received a median number of 5.5 therapies prior to their Selinexor trial. They all had relapsed/refractory — to all existing approved therapies — forms of multiple myeloma. All eight of them had received treatment with proteasome inhibitor + immunomodulatory agent and seven of the eight patients had received stem cell transplantations.

Additional Selinexor Trials

Selinexor is not only undergoing trials as a multiple myeloma treatment but also as a possible therapy for refractory prostate cancer, solid tumors, Non-Hodgkin’s Lymphoma (NHL) and Acute Myeloid Leukemia (AML).

Karyopharm Therapeutics Inc (NASDAQ:KPTI) believes that the results of its ongoing Phase 1b food effects study of Selinexor in patients with advanced sarcomas shows continued evidence of the anti-cancer beneficial activity of Selinexor. The company recently reported data covering a range of heavily pretreated — but still progressing — solid tumors including melanoma, ovarian, cervical, and colorectal cancers as well as chemotherapy refractory prostate cancers.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) also claims broad anti-cancer activity and rapid shrinkage of lymph nodes across all varieties of — heavily pretreated — NHL. The company is also happy with the effects of Selinexor in patients with AML.

Quarterly Financial Results

On the financial front, Karyopharm Therapeutics Inc (NASDAQ:KPTI) reported cash and cash equivalents of $144.9 million as of March 31, 2014 compared to $156.0 million as of December 31, 2013. R&D expenditure for 1Q2014 amounted to $11.0 million whereas they were $5.0 million in 1Q2013. The net loss reported in 1Q2014 amounts to $13.7 million compared to a net loss amount of $5.6 million in 1Q2013.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.